Liquidia Co. (NASDAQ:LQDA) Given Average Recommendation of “Moderate Buy” by Analysts

Liquidia Co. (NASDAQ:LQDA) has been given an average recommendation of “Moderate Buy” by the ten brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $24.00.

Several equities analysts recently commented on LQDA shares. Raymond James raised Liquidia from an “outperform” rating to a “strong-buy” rating in a research report on Monday, August 19th. HC Wainwright reissued a “buy” rating and set a $29.00 target price on shares of Liquidia in a research report on Thursday, November 14th. Lifesci Capital assumed coverage on shares of Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price target for the company. Scotiabank started coverage on shares of Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price objective on the stock. Finally, Needham & Company LLC reissued a “buy” rating and issued a $19.00 price objective on shares of Liquidia in a research report on Thursday, November 14th.

Liquidia Price Performance

NASDAQ:LQDA opened at $11.03 on Tuesday. Liquidia has a 12 month low of $7.34 and a 12 month high of $16.99. The business’s 50-day moving average is $10.93 and its two-hundred day moving average is $11.23. The firm has a market capitalization of $933.55 million, a PE ratio of -6.77 and a beta of 0.22.

Insider Buying and Selling at Liquidia

In other Liquidia news, insider Rajeev Saggar sold 2,260 shares of the business’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $25,108.60. Following the completion of the sale, the insider now owns 207,383 shares in the company, valued at $2,304,025.13. The trade was a 1.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Roger Jeffs sold 8,053 shares of the firm’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $89,468.83. Following the completion of the transaction, the chief executive officer now owns 812,193 shares in the company, valued at approximately $9,023,464.23. The trade was a 0.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,007 shares of company stock worth $245,780 over the last quarter. 30.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Liquidia

Several institutional investors have recently made changes to their positions in the stock. Whitefort Capital Management LP boosted its position in Liquidia by 119.8% during the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock valued at $17,020,000 after purchasing an additional 927,546 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Liquidia by 144.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock valued at $3,903,000 after buying an additional 230,820 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Liquidia by 18.2% during the second quarter. Bank of New York Mellon Corp now owns 207,961 shares of the company’s stock valued at $2,496,000 after acquiring an additional 32,076 shares during the period. HighVista Strategies LLC grew its position in shares of Liquidia by 48.6% during the third quarter. HighVista Strategies LLC now owns 180,947 shares of the company’s stock worth $1,809,000 after acquiring an additional 59,193 shares during the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of Liquidia by 12.5% in the 3rd quarter. Wellington Management Group LLP now owns 179,923 shares of the company’s stock worth $1,799,000 after acquiring an additional 19,932 shares during the period. 64.54% of the stock is owned by institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).